^
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
FDA - 1 week - (New A1)
No biomarker
Ependymoma
lomustine
Sensitive: A2 - Guideline
No biomarker
Ependymoma
etoposide IV
Sensitive: A2 - Guideline
No biomarker
Ependymoma
lapatinib
Sensitive: A2 - Guideline
No biomarker
Ependymoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Ependymoma
bevacizumab
Sensitive: A2 - Guideline
CDK4 overexpression
Ependymoma
abemaciclib
Sensitive: D – Preclinical
CCND1 overexpression
Ependymoma
abemaciclib
Sensitive: D – Preclinical